MINNEAPOLIS, Minnesota, May 17 /PRNewswire/ -- Coloplast Corp. announced today that they have signed an agreement with Carbon Medical Technologies, Inc., giving Coloplast Corp. exclusive US distribution rights to Durasphere(R) EXP injectable bulking agent and it's new needle delivery system. The clinically proven bulking agent will be available from Coloplast beginning in June 2007.
Durasphere(R) EXP Injectable Bulking Agent is composed of pyrolytic carbon coated beads suspended in a water-based carrier gel and is indicated for the treatment of adult women with stress urinary incontinence ("SUI") due to intrinsic sphincter deficiency. Durasphere(R) EXP is injected in order to augment the soft tissue around the urethra to close the bladder neck and restore normal urinary control.
Commenting on the performance of Durasphere(R) EXP, Dr Kathleen C. Kobashi, Co-Director, Continence Center at Virginia Mason and Clinical Associate Professor, University of Washington in Seattle, stated, "In my experience, the Durasphere(R) EXP injectable agent has been very effective in treating female incontinence due to intrinsic sphincter deficiency, and we anticipate continued improvements through Coloplast's involvement."
In the US alone, over 15 million women suffer from SUI. While not a life Threatening disease it is one that has serious adverse effect on the quality of a woman's life. The number of women suffering from SUI is projected to increase based on the aging of the U.S. population. Injectable urethral bulking agents represent an alternative to surgical approaches for the relief of SUI and its often-debilitating symptoms.
"Coloplast is excited to distribute this minimally-invasive therapy for female stress urinary incontinence," said Jan Rolin Frederiksen, President of Coloplast USA. "Durasphere(R) EXP is a natural strategic extension of our growing Women's Health franchise, and provides an effective, easy-to-use solution for treating stress urinary incontinence in women. Additionally, Carbon Medical Technologies' new needle design overcomes many of the delivery challenges previously experienced with bulking agents - potentially setting a new standard in injectable procedure reproducibility."
Coloplast Corp. 200 South 6th Street, suite 900, Minneapolis, MN 55402, www.us.coloplast.com
Coloplast develops, manufactures and markets medical devices and services to an increasing number of users all over the world. Our business areas include ostomy care products; urology & continence care products and products for wound & skin care. We work closely with health care professionals and product users in creating new and innovative products and services. We employ approximately 7,000 people.
CONTACT: Contacts: Ash Keswani, Vice President of Surgical Urology,+1-612-302-4970 or +1-612-770-4783, USAKE@coloplast.com; Maria Toso,Communications Consultant, +1-612-337-7954, USMATO@coloplast.com